Cross Reactive Carbohydrate
Cross Reactive Carbohydrate - Related Videos
00:42
Cross-reactivity
0 Views •
2025
Overview The ability of a single antibody to recognize multiple structurally similar epitopes is an important immune defense strategy that enables the host to efficiently defend against many potentially threatening pathogens. However, cross-reactivity also elicits allergy symptoms against related allergens. It is increasingly important to understand the principles of cross-reactivity, as antibodies are actively being developed as therapeutic modalities for diverse diseases, including cancer.
10:44
Snap Chip for Cross-reactivity-free and Spotter-free Multiplexed Sandwich Immunoassays
0 Views •
Cited by 3 •
2017
We demonstrate a snap chip technology for performing cross-reactivity-free multiplexed sandwich immunoassays by simply snapping two slides. A snap apparatus is used for reliably transferring reagents from microarray-to-microarray. The snap chip can be used for any biochemical reactions requiring colocalization of different reagents without cross-contamination.
04:36
A Snap Chip Technology for a Cross-Reactivity-Free Multiplexed Sandwich Immunoassay
0 Views •
2025
The video showcases the implementation of snap chip technology for cross-reactivity-free multiplexed sandwich immunoassays. The simple action of snapping two microarray slides, each containing different reagents, ensures reagent transfer without cross-contamination and helps to detect multiple proteins using sandwich immunoassay.
12:30
Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77
0 Views •
Cited by 4 •
2015
Here, we selectively target antibodies against a specific member of a highly conserved family of proteins by immunizing animals with their most divergent regions followed by removing cross reactive antibodies by pre-adsorption.
09:28
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
0 Views •
Cited by 12 •
2010
The urease method of sample preparation for GC/MS analysis of intermediary metabolites is presented by its inventor. The method allows one-step follow-up of newborn screening for inborn errors by tandem mass spectrometry by quantifying carbohydrates, organic and amino acids all in a single process.
FAQs
Shared carbohydrate epitopes provide the molecular basis for this pattern. IgE antibodies produced after recognition of a carbohydrate structure in one allergen source may bind a comparable structure on glycoproteins from another source. The assay therefore detects antibody binding based on structural similarity, not necessarily exposure to each tested allergen.
CCD-related binding can create a positive laboratory result without corresponding symptoms. This occurs because the measured signal reflects IgE recognition of a shared carbohydrate structure, whereas clinical relevance depends on whether the patient experiences symptoms associated with the allergen source. Consequently, a positive test should not be interpreted in isolation.
Plant, insect, and venom extracts are important because their glycoproteins may carry carbohydrate structures that resemble those found in unrelated allergen sources. Testing with these extracts can therefore reveal a shared antibody-binding pattern rather than several independent clinically meaningful sensitizations. Recognizing the source pattern helps explain apparently broad laboratory reactivity.
Clinicians should compare the laboratory pattern with the patient’s symptoms and the relevant allergen sources. When several results indicate antibody binding but lack corresponding clinical findings, CCD reactivity may account for misleading sensitization signals. This contextual interpretation helps distinguish clinically relevant sensitization from assay cross-reactivity during allergy assessment.
A CCD-related pattern provides context for evaluating whether positive allergy results reflect clinically relevant sensitization. It alerts clinicians that antibody binding to plant, insect, or venom extracts may arise from shared carbohydrate structures. This consideration improves interpretation of laboratory findings and reduces the risk of treating every positive result as evidence of symptomatic allergy.
Recognizing CCD reactivity supports more accurate diagnosis and management by placing laboratory findings alongside the patient’s actual clinical presentation. It can identify results that may be misleading because of cross-reactive carbohydrate recognition, helping clinicians focus attention on sensitizations that better correspond to symptoms. The result is a more informed assessment of the patient’s allergy profile.